Michael E. Sturmer Sells 4,515 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) President Michael E. Sturmer sold 4,515 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total value of $144,254.25. Following the sale, the president now directly owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Progyny Trading Down 1.1 %

NASDAQ:PGNY opened at $31.72 on Friday. The firm has a market cap of $3.05 billion, a PE ratio of 51.16, a price-to-earnings-growth ratio of 1.34 and a beta of 1.51. The stock has a fifty day moving average price of $35.24 and a 200 day moving average price of $35.58. Progyny, Inc. has a 12-month low of $29.44 and a 12-month high of $44.95.

Progyny (NASDAQ:PGNY) last released its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million during the quarter, compared to analyst estimates of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. Progyny’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the business posted $0.03 earnings per share. Equities analysts forecast that Progyny, Inc. will post 0.7 EPS for the current year.

Analyst Ratings Changes

PGNY has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $48.00 target price on shares of Progyny in a research note on Wednesday, February 28th. SVB Leerink began coverage on Progyny in a research note on Monday, February 26th. They issued an “outperform” rating and a $49.00 price objective for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Truist Financial reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Progyny in a research note on Wednesday, April 17th. Finally, KeyCorp dropped their price objective on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Buy” and a consensus target price of $48.30.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. RiverPark Advisors LLC lifted its holdings in Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock worth $40,000 after buying an additional 374 shares during the last quarter. TFC Financial Management Inc. purchased a new stake in Progyny during the 1st quarter worth about $42,000. Financial Management Professionals Inc. purchased a new stake in Progyny during the 1st quarter worth about $52,000. Acadian Asset Management LLC purchased a new stake in Progyny during the 3rd quarter worth about $53,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Progyny by 9.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock worth $115,000 after buying an additional 264 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.